Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2024 first-quarter earnings
Q1 2024-1x1.png

What you need to know about Johnson & Johnson’s 2024 first-quarter earnings

Here’s an infographic breakdown of the company’s first-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

Share Article
share to

This morning, Johnson & Johnson shared its 2024 first-quarter earnings report.

Since its founding in 1886 the company has been committed to innovation—today, more than 130,000 employees across the globe work to deliver solutions for patients around the world and to help profoundly impact health for humanity.

“This quarter’s solid financial results and the significant advancement of our pipeline further progressed our business toward future growth,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Our strong financial foundation and commitment to operational excellence enables us to continue to invest in innovation that delivers novel treatments for our patients, enhance our portfolio through strategic acquisitions, and return capital for our shareholders, as evidenced by our 62nd consecutive year of dividend increases announced today

For more details about the company’s 2024 first-quarter results and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.


Q1 2024 Earnings Infographic

Johnson & Johnson’s 2024 1st-quarter earnings

Read the earnings press release, which includes full financial data for the first quarter of 2024.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.